The Transfar Biomanufacturing Pilot Platform has been included in the list of the first batch of national pilot platforms for biomanufacturing capacity development

Thread Content

Transfar’s Biomanufacturing Pilot Platform Makes It onto the Initial List 2025-11-20 13:25:48 Recently, the Ministry of Industry and Information Technology together with the National Development and Reform Commission announced the list of the first batch of platforms for building biomanufacturing pilot capabilities in China; a total of 43 organizations were selected for this list. The “Hangzhou Synthetic Biology Industry Pilot (Validation) Center,” developed and operated through a partnership between Transfar Group and state-owned capital, was successfully selected as one of the representative platforms in Zhejiang Province. This marks **level authoritative recognition** of Transfar Group’s technical expertise and industrialization capabilities in the field of synthetic biology. Biomanufacturing is one of the key future industries that China focuses on developing. Vigorously promoting biomanufacturing is of great significance for transforming traditional manufacturing models, creating new drivers for economic growth, facilitating the green transformation of industries, and helping to achieve the \"dual carbon\" goals. The pilot-scale testing phase represents the \"last mile\" for translating innovations in biotechnology from the laboratory to industrial application; it is also a key factor in overcoming critical barriers and improving the industrial ecosystem. The release of this first list of pilot-scale platform capabilities across the country is aimed at accelerating the resolution of weaknesses in the pilot-scale production phase of biomanufacturing in China, as well as promoting the improvement of the industrial ecosystem and the efficient transformation of innovative achievements. The Hangzhou Synthetic Biology Industry Pilot (Validation) Center is located in the Xiaoshan Green Manufacturing Industrial Park. It focuses on the pilot testing and scale-up of synthetic biology technologies, covering various fields such as bio-manufactured chemicals, enzyme preparations, foods, and additives. The center aims to create a comprehensive platform that integrates technical pilot testing, result validation, process scale-up, and industrial transformation. At present, the pilot (validation) center, leveraging Transfar Group’s advanced manufacturing framework and the innovation platform of Transfar Science and Technology City, has established and is developing various pilot-scale application scenarios and testing systems. It is equipped with multi-level fermentation, catalysis, and separation equipment ranging from 0.1 liters for lab-scale experiments to 1000 liters for pilot-scale operations, enabling full-process development and validation from strain design, fermentation scale-up, enzyme-catalyzed conversion to product purification. In the pilot project for bispyribac-sodium, the center developed a process system that encompassed multiple stages such as biological fermentation, cell collection, enzyme-catalyzed conversion, and product purification. It was equipped with specialized equipment including fermentation tanks, reaction vessels, ceramic membrane filters, and distillation towers, enabling the successful scale-up of the key product from laboratory results to industrial-scale samples. At the upstream stage, the pilot (validation) center has developed its own high-throughput bio-fabrication platform, which integrates advanced analytical instruments such as liquid chromatography-mass spectrometry and PCR, and possesses core capabilities in strain design, high-throughput testing, and process validation. The platform also actively promotes the application of AI technology in synthetic biology, providing intelligent support for process optimization and parameter control, thereby establishing a pilot-scale capability system that covers the entire process of synthetic biology. Yao Chenpeng, vice president of Transfar Group, said that being selected as part of **the first batch of biomanufacturing pilot-scale production capacity development platforms is a high recognition of Transfar’s leadership role in driving continuous innovation and industrial transformation in the field of biomanufacturing. Taking this as an opportunity, the group will continue to focus on emerging industries such as synthetic biology and green chemistry, strengthen collaborative innovation among industry, academia, and research institutions, optimize pathways for its own transformation, upgrading, and high-quality development, and contribute to the formation of a regional biotechnology industry cluster. During its construction, the center has undertaken 11 pilot projects, serving as a valuable \"testing ground\" for various new technologies, processes, and products, thereby accelerating the transformation of research achievements. In the future, the pilot (validation) center will continue to improve its pilot-scale equipment and services, enhance standards and levels of automation, and further empower biomanufacturing companies. It will provide replicable and scalable models for the industrialization of synthetic biology technologies, thereby injecting new momentum into the high-quality development of the bioeconomy.